Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

llion.

"While, clearly the early part of 2009 produced disappointing clinical results for maribavir, 2008 was a very successful year for ViroPharma -- from strong financial results to great execution in all aspects of our business to the transformational acquisition of Lev Pharmaceuticals and the launch of Cinryze. As a result we believe we have positioned ourselves with a number of growth drivers and multiple opportunities for success," stated Vincent Milano, ViroPharma's president and chief executive officer. "Those who follow our company can look for a number of exciting milestones throughout the upcoming year, such as progress on Cinryze, including the ongoing commercial launch and our acute indication sBLA with a June PDUFA date; continued success with Vancocin; the planned initiation of clinical studies for NTCD; and continued strong financial performance."

Net sales of Vancocin were $50.0 million for the fourth quarter of 2008 and $232.3 million for the year ended December 31, 2008, as compared to $47.7 million and $203.8 million in the respective 2007 periods.

Operating income for the year ended December 31, 2008 was $78.7 million. Our operating loss for the fourth quarter 2008 was $3.4 million. These amounts are compared to operating income of $115.8 million and $19.0 million for the year and fourth quarter of 2007, respectively. Operating income decreased in both comparative periods primarily due to increased amortization expense, the growth in the investment in our pipeline and increased SG&A costs.

Net loss in the fourth quarter ended December 31, 2008 was $1.0 million, compared to net income of $20.4 million for the same period in 2007. For the twelve months ended December 31, 2008, net income was $67.6 million, compared to $95.4 million for the same period in 2007. Net loss per share for the quarter ended December 31, 2008 was $0.01 per share, basic and
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... An analysis of patented university inventions licensed to ... path to commercialization. To open these roadblocks, the ... results during the discovery stage could lead to ... are frequently derived from discoveries made in university ... well known during clinical trials, which have a ...
(Date:8/20/2014)... , Aug. 20, 2014  Decision Resources Group finds that ... Russia , India and ... billion in 2013, roughly equal to the size of ... the BRIC market will experience much faster growth as a result ... population. Other key findings from Decision Resources Group,s coverage ...
(Date:8/20/2014)... in your ear could improve the health of your ... University of Leeds used a standard TENS machine like ... pulses to the tragus, the small raised flap at ... the ear canal. , The stimulation changed the influence ... the nervous signals that can drive failing hearts too ...
(Date:8/19/2014)... and Markets  has announced the addition of the "Cell and ... their offering. This report analyzes the worldwide markets ... following Product Segments: Media, Sera, and Reagents. The report ... , Japan , Europe , ... . Annual estimates and forecasts are provided for the period 2013 ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3'Tickling' your ear could be good for your heart 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2
... SAN DIEGO, Nov. 20 Veridiam (www.veridiam.com) won the ... the 2009 Workplace Excellence Awards. The awards are sponsored ... and recognize innovative and exceptional human resources practices. , ... than 129 employee-nominated companies, honored at the recent awards ...
... ... webinar, “Roller Compactions Process Optimization Using At-Line Particle Characterization”, will be presented on December ... demonstrated to map the design space and optimize a series of roller compaction runs ... ...
... Dr. Mate Hidvegi, inventor of Avemar fermented wheat germ extract, ... Biropharma Kft, discrediting the Hungarian company for making false and ... Dr. Hidvegi stated from his office in Budapest, Hungary: ... apply to AveULTRA, www.aveultra.com , is misleading. ...
Cached Biology Technology:Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Roller Compaction Process Optimization Using At-Line Particle Characterization 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2
(Date:8/20/2014)... are athletes who have suffered concussions ready to return ... found that high school athletes who head back on ... a significant regression in their abilities to simultaneously walk ... seen in changes in their balance and/or altered walking ... of the 12 had returned to activity in less ...
(Date:8/20/2014)... one day be made out of cocoa, rice and ... The novel process they developed and their results, which ... plastic waste problems, appear in the ACS journal ... colleagues at the Italian Institute of Technology point out ... production reached 288 million tons worldwide, but its ubiquity ...
(Date:8/20/2014)... have developed methods for electronically manipulating the flight muscles ... use to control those muscles. The work opens the ... for use in emergency response. , "In the big ... the movement of moths for use in applications such ... an assistant professor of electrical and computer engineering at ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3Research paves way for development of cyborg moth 'biobots' 2
... Research Institute is reporting a discovery that sheds light ... the normal processes that govern the everyday life of ... diseases, including cancer and septic shock. , The discovery ... their relationship to the genetic transcripts known as messenger ...
... to fathom a proverb ?catch the figurative meaning of "an ... research led by V. S. Ramachandran, director of the Center ... Diego, a region of the brain known as the angular ... ability to understand metaphor. , Ramachandran and colleagues tested four ...
... by a team of researchers at Penn State, which also ... to control tissue growth. The team's genetic and biochemical studies ... the journal Cell. "This discovery extends our understanding of how ... the formation of tumors, and it raises the possibility that ...
Cached Biology News:Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression 2Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression 3Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression 4Grasping metaphors: UC San Diego research ties brain area to figures of speech 2New tumor-suppressor gene discovered 2New tumor-suppressor gene discovered 3New tumor-suppressor gene discovered 4
Fingerprinting II database sharing tools is an optional module for the Fingerprinting II Basic software package that enables peer-to-peer data exchange over the internet and provides external databas...
... Fingerprinting II Informatix ... an optional module ... component analysis, multidimensional ... and MANOVA, and ...
Fingerprinting II comparative quantification and polymorphism analysis is an optional module that adds comparative quantification and polymorphism analysis functions to the Fingerprinting II Basic so...
... is the most advanced thermal cycler ever ... performance, the Dyad also boasts graphical programming ... navigation via touch pad or mouse. ... economically expanded to a four-bay system with ...
Biology Products: